Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor

Currently, there is no medication available to adequately treat patients undergoing hemodialysis who are suffering from intradialytic hypotension (IDH). Medical interventions such as Trendelenburg positioning, saline bolus administration, reduction of ultrafiltration rate, interruption of the hemodialysis, and other medical treatments are the methods of choice to treat the hypotensive condition of these patients and thus to maintain the systolic blood pressure. Patients suffering from IDH have a higher reported mortality rate due to the given stress on their cardiovascular system. New treatments, therefore, would give clinicians an additional alternative to current existing approaches and might help patients to maintain their blood pressure during hemodialysis. The main objective of the study is to evaluate the efficacy of icatibant in the prevention of systolic blood pressure (SBP) drop in patients on hemodialysis suffering from recurrent IDH episodes during hemodialysis.

NCT Number	NCT05834777
Lead Sponsor	Vanderbilt University Medical Center Collaborators: Pharvaris Netherlands B.V., Renal Research Institute
Conditions	Intradialytic Hypotension
Enrollment	26 participants
Start Date	2023-12-11
Primary Completion	2026-07-01 (estimated)
Study Completion	2026-11-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-15